Kyu Seop Kim1, Won Ki Lee2. 1. Department of Ophthalmology, Seoul St. Mary's Hospital, The Catholic University of Korea, #505 Banpo-Dong, Seocho-Gu, Seoul, 137-701, Korea. 2. Department of Ophthalmology, Seoul St. Mary's Hospital, The Catholic University of Korea, #505 Banpo-Dong, Seocho-Gu, Seoul, 137-701, Korea. wklee@catholic.ac.kr.
Abstract
PURPOSE: To report the efficacy of intravitreal bevacizumab for either recurrent or persistent serous changes originating from a persistent branching vascular network or secondary choroidal neovascularization after photodynamic therapy for polypoidal choroidal vasculopathy, despite regression of polypoidal lesions. METHODS: Twenty eyes of 20 patients with at least 12 months of regular follow-up were retrospectively reviewed. Intravitreal bevacizumab was administered on an as-needed basis, guided by optical coherence tomography (OCT), after the first injection. RESULTS: Seventeen (85%) of 20 eyes showed resolution of macular fluid after a mean of 1.9 (range 1-3) consecutive injections; however, 15 (88%) of them had relapsing episodes of fluid collection. The mean number of injections needed was 4.2 (range 1-6) over a period of 12 months. At 12 months, 10 eyes (50%) had no fluid accumulation on OCT, while 10 eyes (50%) had some residual fluid. The mean central foveal thickness improved significantly from 280 ± 37 to 226 ± 62 μm (P = 0.002). Visual acuity was maintained or improved in 16 eyes (80%). CONCLUSIONS: Intravitreal bevacizumab appears to be effective in resolving intraretinal and subretinal fluid originating from these lesions. However, the favorable effect was maintained for only a limited period of time and required repeated injections.
PURPOSE: To report the efficacy of intravitreal bevacizumab for either recurrent or persistent serous changes originating from a persistent branching vascular network or secondary choroidal neovascularization after photodynamic therapy for polypoidal choroidal vasculopathy, despite regression of polypoidal lesions. METHODS: Twenty eyes of 20 patients with at least 12 months of regular follow-up were retrospectively reviewed. Intravitreal bevacizumab was administered on an as-needed basis, guided by optical coherence tomography (OCT), after the first injection. RESULTS: Seventeen (85%) of 20 eyes showed resolution of macular fluid after a mean of 1.9 (range 1-3) consecutive injections; however, 15 (88%) of them had relapsing episodes of fluid collection. The mean number of injections needed was 4.2 (range 1-6) over a period of 12 months. At 12 months, 10 eyes (50%) had no fluid accumulation on OCT, while 10 eyes (50%) had some residual fluid. The mean central foveal thickness improved significantly from 280 ± 37 to 226 ± 62 μm (P = 0.002). Visual acuity was maintained or improved in 16 eyes (80%). CONCLUSIONS: Intravitreal bevacizumab appears to be effective in resolving intraretinal and subretinal fluid originating from these lesions. However, the favorable effect was maintained for only a limited period of time and required repeated injections.
Authors: Rogério A Costa; Eduardo V Navajas; Michel E Farah; Daniela Calucci; Jose A Cardillo; Ingrid U Scott Journal: Prog Retin Eye Res Date: 2005-04-18 Impact factor: 21.198
Authors: Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-10-20 Impact factor: 3.117
Authors: Ziad F Bashshur; Zeina A Haddad; Alexandre Schakal; Rola F Jaafar; Marc Saab; Baha' N Noureddin Journal: Am J Ophthalmol Date: 2007-12-11 Impact factor: 5.258
Authors: Wai-Man Chan; Dennis S C Lam; Timothy Y Y Lai; David T L Liu; Kenneth K W Li; Yi Yao; Tak-Hung Wong Journal: Ophthalmology Date: 2004-08 Impact factor: 12.079
Authors: Kai Tang; Jun-Kang Si; Da-Dong Guo; Yan Cui; Yu-Xiang Du; Xue-Mei Pan; Hong-Sheng Bi Journal: Int J Ophthalmol Date: 2015-10-18 Impact factor: 1.779